| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 3.38 Billion | USD 11.19 Billion | 14.22% | 2023 |
According to a report from Zion Market Research, the global drug discovery informatics market was valued at USD 3.38 billion in 2023 and is projected to hit USD 11.19 billion by 2032, with a compound annual growth rate (CAGR) of 14.22% during the forecast period 2024-2032. This report explores market strengths, weaknesses, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Drug Discovery Informatics Market industry over the next decade.
The drug discovery informatics market is about to realize momentum within the coming years, owing to advancements in high-performance computing & web services, the growing volume of drug discovery data, the growing adoption of in-silico modeling tools, and the increasing demand for novel medicine moieties. The launch of advanced drug discovery information technology is about to accentuate the industry competition. For Instance, in January 2021, Certara, Inc. launched Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform version 20. The new models help in analyzing and assessing drug action during lactation and pregnancy.
Drug discovery is a hazardous process that requires much time to invent a drug for any disease or disorder. During the invention procedure, it generates a huge amount of data which can be further utilized during a clinical study or other during other invention. This data can be stored manipulate and retrieved through the drug discovery analytics.
In addition, it helps the purchasers with critical decisions regarding optimizing medication safety and efficacy profile. Companies are also increasingly adopting informatics solutions to shorten the long drug discovery timeline. As an example, in December 2020, Curve Therapeutics Ltd. implemented the CDD Vault platform for handling its genetically encoded Microcycle platform. It's a ubiquitous hosted platform suitable for applications across biotechnology, pharmaceutical & academic institutes for securing and seamless sharing of knowledge in real-time, thereby facilitating collaborative discoveries.
The impact of COVID-19 is supposed to be for a short range; however, its impact is going to have a vast effect on the drug discovery companies, forecast to have a big scope for a minimum of a year to 12-15 months. This led to organizations capitalizing more on solutions and services to sustain operations. Governments are declaring packages to assist businesses during this pandemic, with a special specialization in Small & Medium-scale Enterprises. Besides, the accelerated COVID-19 drug discovery around the world is additionally contributing to the market growth. For instance, providing fast-track solutions, scientists executed virtual screening using medicine from the DrugBank, for targeting the viral proteins and human ACE2 receptors. These studies were supported by in silico tools for screening small molecules that have the potential for use in drug discoveries against COVID-19.
Companies are also developing several web services & solutions to support various steps of drug development for COVID-19. For example, in June 2020, the IBM Visual Molecular Explorer platform explored a specific set of generated molecules targeting the coronavirus (SARS-CoV-2). The open-source sharing of the AI-generated artifacts within the explorer helped in the initial stages of optimal medicine design.
Market growth is essentially driven by factors like the increasing R&D expenditure, budding support for research, particularly within the area of rare diseases, and therefore the growing use of informatics in drug discovery. Players across the drug discovery informatics market are concentrating aggressively on innovation, as well as on including advanced technologies in their existing products. Over the approaching years, they're also expected to require partnerships and mergers & acquisitions as their key strategy for business development. However, the scarcity of expert professionals and the high setup cost of informatics Outsourced Informatics is anticipated to limit market growth to a particular extent.
Drug discovery analytics is a special kind of application or software that can store and retrieve the structured and unstructured data that is generated during the drug discovery process. The drug discovery analytics helps to reduce the cost of treatment, and it provides efficient and accurate data. This kind of data is utilized further by R&D, pharmaceutical, biotech companies, and physicians.
The drug discovery informatics market is primarily driven by rising demand for computational technology in the medical industry. Use of computational technology offers the fastest and most accurate data to the end-users. However, critical attributes of data evaluation in drug discovery informatics are a major restraint that is likely to impede the growth of the market. Nonetheless, the adoption of computational technology in emerging economies is expected to open new opportunities for market participants in the near future.
| Report Attributes | Report Details |
|---|---|
| Report Name | Drug Discovery Informatics Market |
| Market Size in 2023 | USD 3.38 Billion |
| Market Forecast in 2032 | USD 11.19 Billion |
| Growth Rate | CAGR of 14.22% |
| Number of Pages | 210 |
| Key Companies Covered | Certara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., and Illumina, Inc |
| Segments Covered | By Mode, By Services, and By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, the Middle East and Africa (MEA) |
| Base Year | 2023 |
| Historical Year | 2018 to 2022 |
| Forecast Year | 2024 - 2032 |
| Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The drug discovery informatics market is segmented by mode, services, enterprise size, end-use industry, and region.
By Mode Segment Analysis
On the basis of mode, the global drug discovery informatics market is divided into outsourced informatics and in-house informatics. The outsourced segment will expand further at a gentle CAGR during the forecast period on account of an increasing number of partnerships between pharmaceutical companies & contract development and manufacturing organizations. Contract Research Organizations are involved in the creation of reports on new drug entities that are subsequently employed by the drug manufacturer/sponsor for submission to the U.S. FDA. There are benefits when pharmaceutical & biotechnology companies partner with a CRO that has an equivalent informatics solution. The shared informatics platform between the CRO and corporations helps in monitoring the progress of studies in the same way as their internal studies. This helps the corporation in cost-saving and productivity gain, which is predicted to supply the market entities with immense profitable opportunities.
By Service Segment Analysis
Based on services, the global drug discovery informatics market is divided into sequence analysis platforms, docking, molecular modeling, clinical trial data management, and others. The informatics platform enables users to rearrange peptide sequences supported by code by property. Molecular modeling is increasingly gaining popularity due to its wide applications in drug discovery. These tools are used to model & simulate biological systems and small molecules to understand & forecast their behavior at the molecular level. Additionally, they accelerate the cost-efficiency of hit discovery and hit-to-lead optimization.
Globally, North America has been leading the worldwide drug discovery informatics market and is expected to continue in the dominant position for the years to come, followed by Europe. Growing penetration of in-silico technologies, as well as their rampant use witnessed within the region, is the key factor behind the dominance of the North American drug discovery informatics market. The high number of market players headquartered in North America is another significant factor that's supporting this regional market. The APAC drug discovery informatics market is expected to witness swift growth due to the growing presence of pharmaceutical firms alongside the increasing occurrence of cancer ailments in the most populous countries like India and China.
The key players profiled in the report include-
By Mode
By Services
By Enterprise Size
By End Use Industry
By Region
FrequentlyAsked Questions
Drug Discovery Informatics Market size worth at USD 3.38 Billion in 2023
Drug Discovery Informatics Market size worth at USD 3.38 Billion in 2023 and projected to USD 11.19 Billion by 2032, with a CAGR of around 14.22% between 2024-2032.
Escalating demand for quick data access and the rising need for minimizing costs of drug discovery as a result of easy availability of information will spur the drug discovery informatics market.
North America is the largest market for drug discovery informatics in the world. Out of all the 50 states in the country, 49 states have already enacted e-discovery rules. The large share of North America in the global market can be attributed to the presence of well-established CROs, increasing R&D expenditure by pharmaceutical and biopharmaceutical companies.
Key manufacturers included in the study are ertara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., Illumina, Inc. and amongst others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.

Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed